Cargando…

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Y, Thongsawat, S, Gane, E J, Liaw, Y-F, Jia, J, Hou, J, Chan, H L Y, Papatheodoridis, G, Wan, M, Niu, J, Bao, W, Trylesinski, A, Naoumov, N V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618368/ https://www.ncbi.nlm.nih.gov/pubmed/23490388 http://dx.doi.org/10.1111/jvh.12025

Ejemplares similares

Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
por: Leung, Nancy W. Y., et al.
Publicado: (2014)

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B
por: Hou, Jin-Lin, et al.
Publicado: (2015)

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013)

Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
por: Osborn, Melissa K
Publicado: (2009)

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy
por: Piratvisuth, Teerha, et al.
Publicado: (2016)

Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission
por: Ren, Cuicui, et al.
Publicado: (2020)

Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus
por: Zhu, Bo, et al.
Publicado: (2021)

Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART
por: Tsarenko, SP, et al.
Publicado: (2010)

Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study
por: Li, Zhenhua, et al.
Publicado: (2020)

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
por: Zhao, Shushan, et al.
Publicado: (2010)

Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis
por: Liu, Min-Hui, et al.
Publicado: (2013)

Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy
por: Tan, Zhangmin, et al.
Publicado: (2016)

Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study
por: Liang, Jian, et al.
Publicado: (2013)

Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine, Telbivudine, and Tenofovir: A Meta-analysis
por: Sali, Shahnaz, et al.
Publicado: (2019)

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
por: Kim, Eun Hye, et al.
Publicado: (2013)

Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
por: Kim, Young Woon, et al.
Publicado: (2015)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy
por: Zhou, Bin, et al.
Publicado: (2015)

Clinicopathological Features of Telbivudine-Associated Myopathy
por: Ambang, Tomica, et al.
Publicado: (2016)

Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine
por: Li, Yandi, et al.
Publicado: (2022)

Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B
por: Ying, Yue, et al.
Publicado: (2018)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice
por: Lin, Ming-Tsung, et al.
Publicado: (2016)

Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic hepatitis B patient
por: Caroleo, Benedetto, et al.
Publicado: (2013)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021)

Myotoxicity of telbivudine in pre-existing muscle damage
por: Finsterer, Josef, et al.
Publicado: (2010)

Motor development delay in offspring is associated with prenatal telbivudine exposure
por: Zhou, Chengliang, et al.
Publicado: (2018)

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
por: Gan, Weiqiang, et al.
Publicado: (2020)

Effects of Telbivudine Treatment on the Circulating CD4(+) T-Cell Subpopulations in Chronic Hepatitis B Patients
por: Zheng, Yanhua, et al.
Publicado: (2012)

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
por: Lin, Ming-Tsung, et al.
Publicado: (2013)

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
por: An, Jihyun, et al.
Publicado: (2017)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study
por: Krastev, Zahari, et al.
Publicado: (2016)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B
por: Lee, Sangheun, et al.
Publicado: (2015)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy
por: Zeng, Jianyong, et al.
Publicado: (2019)

Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease
por: Lee, Wei-Chen, et al.
Publicado: (2017)

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
por: Zhu, Xiao-Feng, et al.
Publicado: (2011)

Estimated Glomerular Filtration Rate Increases in Chronic Hepatitis B Patients Treated With Telbivudine Monotherapy and Combination Treatment
por: Jiang, Libin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jjgmic901aibsojht15lgfk4i1